Alzheimer's Association Dec 23 2024 We have entered a new era of improved and emerging biologically-based diagnostic biomarkers for Alzheimer's disease (AD) and AD-related neurodegenerative disorders (ADRD) that are rapidly impacting evaluation and care paradigms in every clinical setting: primary care, specialty care and dementia subspecialty care. A comprehensive evaluation includes setting goals in partnership with the patient and usually a care partner; obtaining information about the